Arialys Therapeutics Targets First in Class Precision Therapy for Autoimmune Encephalitis
ART5803 targets NMDA receptor autoantibodies, advancing precision therapy for autoimmune encephalitis.
Shajini
Strategic Industry Context: Alzheimer’s Drug Reimbursement Faces Global Pressure
NICE deems donanemab and lecanemab not cost-effective, blocks NHS coverage for Alzheimer’s drugs.
ENHERTU Advances First-Line Endometrial Therapy in Phase 3 Trial
ENHERTU Phase 3 trial launches for first-line endometrial therapy targeting HER2-expressing tumors.
Alexion Strikes Bold AI Partnership for Rare Disease Detection
AI partnership targets rare bone disease affecting 1 in 6,000 patients.
ZEISS CLARUS 700 Gains China NMPA Approval for Retinal Imaging
ZEISS expands retinal diagnostic capabilities in China with CLARUS 700 ultra-widefield imaging system approval.
GoodRx Disrupts Pharmacy Economics with Cost-Plus Pricing
GoodRx reshapes independent pharmacy economics through transparent cost-plus pricing model launch.
Medacta Showcases Advanced Orthopedic Solutions at ISAKOS
Medacta highlights cutting-edge orthopedic innovations at ISAKOS 2024.
EMA Links Semaglutide to Rare Vision Loss Risk
Two-fold increased risk prompts label updates for blockbuster GLP-1 drugs.
Owens & Minor Scraps $1.4B Rotech Deal Amid FTC Opposition
Medical distributor abandons home healthcare consolidation play.
Dupixent Shows Efficacy in Diverse Patient Population
Dupixent shows 76% efficacy in patients with darker skin tones.